Table 1 Baseline characteristics of randomly assigned participants
IMRT group n = 30 | 3D group n = 30 | p-value | |||
|---|---|---|---|---|---|
n | % | n | % | ||
Age (years) | 0.219 | ||||
Mean (SD) | 66,1 (10,5) | 62,5 (11,8) | |||
Karnofsky-Perfomance Status | 0.283 | ||||
Mean (SD) | 64,9 (9,32) | 61,3 (9,7) | |||
Gender | 0.795 | ||||
Male | 17 | 56,7 | 16 | 53,3 | |
Female | 13 | 43,3 | 14 | 46,7 | |
Weight (kg, SD) | 75,8 (14,9) | 76,2 (19,4) | 0.929 | ||
Height (cm, SD) | 171,6 (8,8) | 172,2 (8,6) | 0.790 | ||
Body mass index (BMI) | 0.960 | ||||
Mean (SD) | 25,7 (4,4) | 25,6 (5,7) | |||
Primary site | |||||
Lung cancer | 11 | 36,7 | 16 | 53,3 | |
ABreast cancer | 7 | 23,3 | 6 | 20 | |
Prostata cancer | 6 | 20 | 1 | 3,3 | |
Other | 6 | 20 | 7 | 23,3 | |
Volume of metastases at baseline | |||||
Mean size (mm3) | 30 | 1166,6 | 30 | 0.191 | |
Localization metastases | 0.261 | ||||
Cervical | 4 | 13,3 | 5 | 16,7 | |
Thoracic | 15 | 50 | 15 | 50 | |
Lumbar | 11 | 36,7 | 7 | 23,3 | |
Sacrum | 0 | 0 | 3 | 10 | |
Number metastases | 0.140 | ||||
1 metastase | 17 | 56,7 | 10 | 33,3 | |
2 metastases | 4 | 13,3 | 9 | 30 | |
3 metastases | 9 | 30 | 11 | 36,7 | |
Distant metastases at baseline | |||||
Viszeral | 14 | 46,7 | 10 | 33,3 | 0.292 |
Lung | 7 | 23,3 | 6 | 20 | 0.754 |
Brain | 4 | 13,3 | 5 | 16,7 | 0.718 |
Tissue | 5 | 16,7 | 5 | 16,7 | 1.000 |
Hormontherapy | 12 | 40 | 6 | 20 | 0.091 |
Immuntherapy | 4 | 13,3 | 5 | 16,7 | 0.718 |
Chemotherapy | 14 | 46,7 | 20 | 66,7 | 0.118 |
Surgery | 18 | 60 | 13 | 43,3 | 0.196 |
Neurological deficit at baseline | 4 | 13,3 | 3 | 10 | 0.688 |
Bisphosphonate at baseline | 13 | 43,3 | 7 | 23,3 | 0.100 |
Orthopedic corset at baseline | 9 | 30 | 10 | 33,3 | 0.781 |
Medication at baseline | |||||
Sleeping medication | 5 | 16,7 | 2 | 6,7 | 0.228 |
Psychiatric medication | 9 | 30 | 6 | 20 | 0.371 |
Opiate | 20 | 66,7 | 17 | 56,7 | 0.426 |
NSAID | 23 | 76,7 | 19 | 63,3 | 0.260 |